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Summary Phospholipid metabolism of human breast cancer was studied by 31p magnetic resonance spectro-
scopy (MRS). In vivo localised 31p MR spectra were obtained from the tumour alone using phase modulated
rotating frame imaging. For 31 tumours, median (range) phosphomonoester (PME) to ATP ratio was 1.48
(0.57-3.78) and phosphodiester (PDE) to ATP ratio was 1.65 (0.44-3.89). DNA index and S phase fraction
(SPF) were measured by flow cytometry of paraffin embedded tissue. Twelve (39%) tumours were diploid and
19 aneuploid. Median (range) SPF for 29 assessable tumours was 5.3% (0.6-28%), with significantly greater
median SPF for aneuploid tumours (9.3%) than diploid (3.8%, P = 0.007). There was a significant association
between PME/ATP and SPF (P= 0.03) due to a significant correlation for aneuploid tumours (P= 0.01).
High resolution 31P MRS of extracts from 18 tumours (including seven studied in vivo) demonstrated that the
PME peak consists predominantly of phosphoethanolamine (PE) with a smaller contribution from phospho-
choline (PC) (median (range) PE/PC: 3.02 (1.13-5.09)). Changes in PME/ATP were observed for two tumours
where tamoxifen stablised disease and may be consistent with the cytostatic effects of this drug.
Breast cancer is the commonest cancer in women with an
annual mortality rate in the United Kingdom of over 14,000
(OPCS Monitor, 1992), and its incidence appears to be rising
in the western hemisphere (Glass & Hoover, 1990). Reduc-
tion in mortality has been reported for mammographic
screening (Shapiro et al., 1982; Tabar et al., 1985) and
adjuvant chemotherapy (Early Breast Cancer Trialists' Col-
laborative Group, 1992a,b). However, many patients with
early breast cancer will relapse with metastatic disease and
about 20% of women present with locally advanced disease.
There is an array of treatment options including endocrine
therapy, cytotoxic chemotherapy and radiotherapy. The
choice of treatment can be guided by prognostic markers, but
assessment of response based on measurement of tumour size
is often delayed, and consequently patients experience toxic-
ity from ineffective treatment. 31p Magnetic Resonance Spec-
troscopy (MRS) may be able to monitor biochemical changes
and offers the potential for early prediction of treatment
response and disease relapse. It may also be useful in assess-
ing biochemical effects of new antitumour agents that are not
directly cytotoxic.
31p MRS provides information on phospholipid metabo-
lism, cellular energetics and intracellular pH. Studies of a
wide range of human tumours in comparison with normal
tissue demonstrate raised phosphomonoesters (PME) (Ober-
haensli et al., 1986; Cadoux-Hudson et al., 1989). Serial 31p
MRS studies in a patient with locally advanced breast cancer
demonstrated a reduction in the level of PME in response to
tamoxifen and cytotoxic chemotherapy (Glaholm et al.,
1989). In another report of three patients with locally
advanced breast tumours, PME/ATP decreased in response
to therapy (Ng et al., 1989). PC and PE are intermediates in
membrane phospholipid biosynthesis (Radda et al., 1989)
and can also be generated by growth factor signalling (Fisher
et al., 1991). The concentration of PME may reflect the rate
of cell membrane synthesis and therefore cellular prolifera-
tion (Radda et al., 1989). This is consistent with the observa-
tion of high concentration of the phosphomonoester, PE in
the developing infant brain (Hope et al., 1984; Younkin et
al., 1984) and liver (Moorcroft et al., 1991), and is further
supported by the increase in PME to ATP ratio during liver
regeneration in the rat following 70% resection (Murphy et
al., 1992). However, alteration in PME associated with
therapy could also be explained by a change in cellular
number, particularly as in most cases there was an associated
change in tumour size. The biochemical basis for therapy
induced changes in PME in human breast cancer detected by
31p MRS is not clear.
The aim of this study was to assess the relationship
between the level of PME measured by 31P MRS in vivo and
proliferation in untreated, primary human breast cancer.
Patients were studied the day before surgery using 31P MRS
and where possible, PME composition of extracts of tumour
were studied by high resolution 31P MRS to aid interpreta-
tion of the in vivo spectra. In addition, elderly patients
treated with tamoxifen were followed with serial 31P MRS
studies.
Materials and methods
Patients
Fifty-seven patients (median age 55 years, range 35-71 years)
with untreated, locoregional breast cancer (UICC Stage TI-4,
N0-1, MO) presenting to the Breast Unit at the John Rad-
cliffe Hospital were studied. The study was approved by the
local ethics committee, and informed consent was obtained
from all subjects. Invasive carcinoma of the breast was con-
firmed in all cases by light microscopy of haematoxylin and
eosin stained sections, and assessment of histological grading
ofductal tumours was based on nuclear pleomorphism, mito-
tic figures and tubule formation. Maximum tumour diameter
was measured from the pathological specimen. Oestrogen
(ER) was determined using the dextran coated charcoal assay
(Leake et al., 1981) and epidermal growth factor receptor
(EGFr) by the radioligand binding assay (Nicholson et al.,
1988). Levels greater than 10 fmol mg-' cytosol protein for
ER, and greater than 20 fmol mg-' membrane protein for
EGFr were taken as positive.
In addition, serial 31P MRS studies were performed in 17
elderly patients (median age 78.5 years, range 71-86 years)
treated with tamoxifen 20 mg twice a day. The diagnosis of
breast cancer was confirmed by fine needle aspirate cytology.
31p MRS was performed before and at intervals during
tamoxifen therapy.
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Controls
31P MR spectra of normal breast were obtained from 14
volunteers (median age 44 years, range 25-82 years) with no
known breast pathology using the same 31P MR protocol as
the patients.
31P MRS in vivo
Localised 31P MR spectra of the breast were obtained on a
Biospec spectrometer interfaced to a 1.9 Tesla, 60 cm clear
bore superconducting magnet (Oxford Research Systems),
operating at 32.7 MHz for phosphorus and 80.8 MHz for
proton. The probe was a double surface coil with the 4 cm
diameter receiver coil electrically isolated from and posi-
tioned 1.5 cm forward from the 10cm diameter transmitter
coil (Styles, 1988). Subjects were positioned supine and
slightly rotated to one side so that the tumour was within the
homogeneous region of the magnet. The magnetic field
homogeneity was optimised by observing the proton signal
from the region of breast to be studied. Depth resolved
spectra were obtained from the tumour separate from the
underlying chest wall muscle using Phase Modulated
Rotating Frame Imaging (PMRFI) as originally proposed by
Hoult (1979) and implemented as described by Blackledge et
al. (1987). Briefly, a total of 16 data accumulations were
acquired, the pulse sequence comprising an incremented
spatial encoding pulse followed by a phase encoding pulse.
Each accumulation comprised 48 transients, collected with an
interpulse delay of 3 s and covering a spectral width of
2000 Hz. Using 100 watts of transmitter power, a pulse
length of 180 fs for both incremental and phase encoding
pulse produced an approximately 90° tip angle in the centre
of the tumour. As there is an inverse relationship between
spatial resolution and signal to noise ratio, the number of
increments was the minimum required for adequate spatial
discrimination. The phosphorus data were collected in 40 min
and the study completed in less than 1 h.
The free induction decays were multiplied by an exponen-
tial line broadening of 15 Hz in the chemical shift dimension
(F2). 2-D Fourier transformation was performed after zero
filling and applying apodisation with a Gaussian function in
the spatial dimension (Fl) (Styles, 1991). From the resulting
2-D data set, tumour spectra were selected by the presence of
PME (undetectable in muscle) and summed to maximise
signal to noise. A frequency domain, Lorentzian line fitting
routine (developed by Counsell C., MRC Radiobiology Unit,
Chilton) was used to measure the area of the peaks in the 31p
MR spectrum after optimising the baseline fit using poly-
nomial corrections. A mean of three fits was used to calculate
PME relative to ATP using the ATP Zy-P signal as the ATP
P-P peak was distorted by off resonance effects (Blackledge &
Styles, 1988). Corrections for partial saturation effects were
not made. For some studies, it was necessary to correct for
contamination of the tumour TyATP signal by muscle. Assum-
ing that PCr could not be detected in tumour, the proportion
of muscle contamination was calculated from the tumour
TATP/PCr ratio using a TATP/PCr ratio of 0.25 measured in
chest wall skeletal muscle. The tumour PME/yATP ratio was
then corrected as appropriate. Empirically, cases with greater
than 40% muscle contamination were excluded from analysis
as the large correction required was likely to introduce large
errors in the value for the PME/yATP ratio.
31P MRS in vitro
Samples of tissue obtained from 18 tumours (including seven
tumours studied by in vivo 31P MRS) were frozen in liquid
nitrogen within 15 min of removal at surgery until the time
of extraction. The tissue was ground to a powder in liquid
nitrogen and homogenised in ice cold perchloric acid (6%
v/v, 4mlg-' tissue). The homogenate was centrifuged and
the supernatant neutralised with 3 M KOH. The resulting
KCI04 precipitate was removed by centrifugation. Chelex 100
(disodium salt) was added to remove the metal ions and
sharpen the spectral lines, and the sample recentrifuged. The
supernatant was lyophilised to dryness overnight. The result-
ing solid was resuspended in 3 ml of double distilled water,
centrifuged to remove residual chelex 100, and adjusted to
pH 8.0-8.5 as there was little variation in chemical shift in
this range of pH.
Fully relaxed 31P MR spectra were obtained on a 9.4 Tesla
magnet, with a repetition time 10 s, sweep width 8064 Hz and
8K data points. Composite pulse proton decoupling was
applied during acquisition (power 3 watts), and gated off
during the relaxation delay to avoid distortion of spectral
intensity by nuclear Overhauser effects. The number of tran-
sients accumulated to achieve good signal to noise varied
with weight of tumour sample. A coaxial capillary containing
methylene diphosphonate acted as a concentration standard.
Chemical shifts were referred to glycerophosphocholine at
2.90 ppm (relative to PCr at 0 ppm) as this resonance is
virtually unaffected by pH or ionic strength changes and was
usually present in the breast tumour extracts. Peak assign-
ments were made on the basis of well established literature
on 31P MR spectra from perchloric acid extracts (Evanochko
et al., 1984; Murphy, 1989) and confirmed by the addition of
known compounds.
DNAflow cytometry
Proliferation was evaluated for all untreated breast tumours
studied by 31P MRS and normal breast tissue from reduction
mammoplasty cases. Flow cytometry was performed on
nuclear suspensions prepared form formalin fixed paraffin
embedded sections as described previously (Camplejohn et
al., 1989). Fifty lim sections were dewaxed and rehydrated
through a series of alcohols into double distilled water.
Nuclei were extracted by the addition of pepsin (5 mg ml-)
at 37°C for 30 min at pH 1.5. Following filtration through a
35 mm pore size nylon filter and incubation with 1 gml-I
DAPI (4'6-diamidino-2-phenylindol-dihydrochloride), the
samples were anlaysed using a Becton Dickinson FACS
Analyser powered by a mercury arc lamp. 105 particles were
scanned to construct a DNA histogram. DNA index was
calculated by relating DNA content of the aneuploid GO/GI
peak to that for the diploid GO/GI peak. The SPF for
diploid tumours was neasured using the method of Baisch et
al. (1975). The number of cells in S phase was calculated
from a rectangle fitted between the peak channels of the
GO/GI and G2/M peaks. For the DNA aneuploid histogram,
the percentage of aneuploid S phase cells as a percentage of
total aneuploid cells was estimated in a similar way (Cample-
john et al., 1989).
Statistical analysis
Non parametric tests, Mann Whitney, Kendall Rank correla-
tion coefficient and Chi squared were used as appropriate.
Results
31P MRS in vivo
Interpretable in vivo 31p MR spectra were obtained from
31/57 (54%) breast tumours studied prior to surgery. The
patient characteristics are listed in Table I. Inadequate signal
to noise and/or spatial resolution prevented analysis in 26
tumours. About one third of tumours (9/26) were less than
2cm in diameter.
Figure 1 shows a typical contour plot where the contour
lines represent intensity levels of the 31P MR signal. The
tumour at the front of the spectroscopic image contains high
levels of PME and PDE. There is no detectable PCr. In
contrast, the muscle at the back of the image contains PCr,
ATP and Pi. The median PME/yATP was 1.48 (range: 0.57-
3.78) and median PDE/yATP was 1.65 (range: 0.44-3.89).
Figure 2 shows a typical in vivo 31P MR spectrum from
normal breast. In all cases, there was very poor signal to31p MRS OF HUMAN BREAST CANCER AND PROLIFERATION 1147
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Figure 1 PMRFI data set from breast cancer represented as a contour plot with chemical shift represented on the horizontal axis
and depth along the vertical axis, and selected spectra from the tumour at the front of the plot and underlying chest wall muscle at
the back of the plot. PME = phosphomonoester, Pi = inorganic phosphate, PDE = phosphodiester, ATP = adenosine triphosphate.
Table I Clinical details of breast cancer patients (n = 31)
Age (years)
Median
Range
Menopausal status
Pre-menopausal
Post-menopausal
Tumour diameter
.2cm
2<5cm
>5cm
Histology
Invasive ductal
Grade I
Grade II
Grade III
Not classified
Invasive lobular
Mixed ductal + lobular
Axillary node status
Negative
Positive
Unknown
ER
< 10 fmol mg- protein
>10 fmol mgl protein
EGFr
<20 fmol mg-' protein
>20 fmolmg-' protein
Unknown
DNA index
Diploid
Aneuploid
1.1-1.9
2.0-3.0
SPF median (range)
n = 29 All
n = 11 Diploid
n= 18 Aneuploid
54
35-71
9
22
3
24
4
25
0
12
12
1
4
2
16
14
1
14
17
16
13
2
12
15
4
5.3% (0.6-28%)
3.8% (1.3-6.5%)
9.4% (0.6-28%)
noise indicating that the total level of phosphorus-containing
metabolites was much lower than in breast cancer.
31P MRS in vivo and tumourproliferation
DNA histograms could be interpreted for 29 tumours (coeffi-
cient of variation >8% for excluded cases). Twelve (39%)
were diploid and 19 aneuploid. The median (range) SPF for
all tumours was 5.3% (0.6-28%). The median (range) SPF
for aneuploid tumours (9.3% (0.6-28%)) was significantly
higher than for diploid tumours (3.8% (1.3-6.5%)) (P=
0.007).
DNA histograms could be evaluated for 6/8 normal breast.
All were diploid and the median (range) SPF was 1.4%
(1.0-1.8%). The median SPF for normal breast was signi-
ficantly lower than for both diploid (P = 0.007) and aneu-
ploid tumours (P = 0.0005).
There was a significant association between PME/yATP
and SPF (P = 0.03) for all tumours (Figure 3a) due to a
significant relationship for the aneuploid tumours (P = 0.01)
(Figure 3b). No relationship between SPF and PME/yATP
was observed for diploid tumours (Figure 3c). Some diploid
tumours with low SPF values had moderate PME/yATP
ratios. No significant association was found between the
relative level of PME and DNA ploidy (P = 0.39).
31P MRS in vivo and otherpresentationfeatures
Median tumour diameter was 3.0 cm (range 1.5-15 cm)
(Table I). Histological grade was documented for 24/25
(96%) invasive ductal carcinomas. Equal numbers were des-
cribed as moderately well and poorly differentiated. Axillary
lymph node metastases were present in 14/30 (45%). ER was
recorded for all tumours, 17 (55%) had values greater than
10 fmol mg' cytosol protein and were therefore positive. No
significant association was observed between PME/yATP and
. 'I - - --
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Figure 2 31P MR spectrum from normal breast (age 33) with very poor signal to noise.
tumour size (P = 0.60), histological grade (P = 0.93), axillary
lymph node status (P = 0.37) or ER status (P = 0.87).
The median EGFr for 29 tumours was 17.2 fmolmg-'
membrane protein (range: 0-148 fmolmg-' membrane pro-
tein). Sixteen (55%) were positive with values greater than
20 fmol mg-' membrane protein. No relationship was found
between PME/yATP and the level of EGFr (P = 0.75) or
EGFr status (P = 0.14).
31P MRS in vivo and the effect oftamoxifen
Serial 31P MRS studies were not evaluable for 14/17 patients
due to poor signal to noise for seven tumours, inadequate
localisation for five tumours, and refusal for repeat studies
for two patients. The results for three patients with evaluable
long term 31P MRS studies are presented.
Case 1 A 82 year old woman presented with tumour mea-
suring 6 x 6 cm in the upper part of the right breast. There
was attachment to skin and no sign of fixation to pectoralis
major. There was an enlarged right axillary lymph node. 31P
MRS was performed the day before starting tamoxifen, at 7
days when no change in tumour size was detected, and at 42
days when progressive tumour not responding to tamoxifen
was documented. Tumour size had increased to 7 x 6 cm and
there were multiple skin deposits in the outer part of the
breast. There was progressive increase in PME/-'ATP from
0.52 at day 0 to 0.80 at day 7 (Figure 4), and 1.13 at day 42.
In addition, there was an improvement in signal to noise.
Case 2 A 71 year old women presented with tumour
localised to the upper outer quadrant of the right breast
measuring 5 x 4 cm. Tamoxifen for 17 months stabilised
tumour size. Serial 31P MRS studies detected progressive
reduction in PME/yATP from 2.35 at day 0, to 2.06 at day
86, and 1.27 at day 198. The ratio of PDE/yATP fluctuated
from 3.85 at day 0 to 4.90 at day 86, to 1.63 at day 198. At
17 months, the MRS study was uninterpretable due to spect-
ral contamination from underlying chest wall muscle.
Localisation was poor for this study. The calculated con-
tribution from muscle to the tumour yATP peak was 64%.
Case 3 A 84 year old woman presented with tumour in the
upper part of the right breast measuring 5 x 7 cm. There
were no palpable axillary lymph nodes. 31P MRS on day 7
detected an increase in PME/yATP (day 0: 0.29, day 7: 0.59)
and PDE/yATP (day 0: 1.07; day 7: 1.47), although there had
been no change in tumour size. At day 241, signal to noise in
the tumour spectrum was very poor and resonances from
PDE and Pi could just be detected, although the tumour was
6 x 6 cm. As the quality of the shimming was similar to the
previous MRS studies, the deterioration in the signal to noise
was probably due to a reduction in viable tissue within the
breast tumour.
31P MRS in vitro and identification ofphosphomonoester
Figure 5 shows 31p MR spectra from a human breast cancer
in vivo and in vitro. The PME region consists predominantly
of phosphoethanolamine (PE) and phosphocholine (PC) with
a greater contribution from PE (n = 18, PE/PC: median 3.02,
range 1.13-5.09). There was marked variation in the concen-
tration of PE (median: 1.07fmolg' wet wt, range: 0.23-
2.91 !Lmolg' wet wt) and PC (median: 0.291imol g' wet3'PMRS OF HUMAN BREAST CANCER AND PROLIFERATION 1149
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Discussion
PMRFI provides
the linear radiof
a coil. Calibration experiments using multicompartment phan-
toms show that the 31P MR signal is received from a volume
of tissue approximating to a bell shape 4 cm diameter close
o * * to the coil and increasing to 8.5 cm diameter at 3 cm from
the receiver coil (Dunn et al., 1992). The total volume is
estimated to be 96 cm3. For small tumours, the sensitive
volume detected by the receiver coil contains both malignant
Sr * * and normal breast tissue. However, the paucity of 31P MR
signal detected from normal breast suggests that there was
* * negligible contribution from normal tissue to the tumour
spectra.
0 15 . The aneuploid tumours demonstrated a wide range of
phas f o20 25 30 proliferation whereas the diploid tumours had low prolifer-
S phase fraction b ative activity. The significantly greater median SPF for aneu-
ploid tumours is in agreement with the results of thymidine
labelling studies estimating SPF (McDivitt et al., 1985). Con-
* l l tamination by lymphoid and other diploid non malignant
cells could lead to an underestimate for SPF for the diploid
tumours. This, however, is likely to be insignificant as the
median SPF for diploid tumours (3.8%) was significantly
* * greater than for normal breast (1.4%). SPF for normal breast
were in a narrow range with very low levels.
* * There was a strong relationship between tumour prolifera-
tion and PME/yATP due to a highly significant correlation
510 1'5 20 25 30 for aneuploid tumours. No relationship was observed for
Sphasefraction/aneuploidtumours diploid tumours. Studies have shown that abnormal DNA
C ploidy is indicative of aggressive growth as aneuploid
tumours have a worse prognosis than diploid tumours
(Hedley et al., 1987; Merkel & McGuire, 1990) although this
finding is not universal (O'Reilly et al., 1990). The range of
SPF values for diploid tumours (1.6-6.5%) suggests that the
majority of cells in these tumours are not proliferating. The
G predominant cell population will determine the composition
of the 31P MR spectrum. Therefore, a relationship between
PME and proliferation would not be detected if the PME
content of proliferating cells was not greatly elevated. In
support, actively growing human breast cancer cells in cul-
10 15 20 25 30 ture contain approximately twice the amount of PE and PC
than quiescent cells (Daly et al., 1987). S phase fraction/diploid tumours For the breast cancer extracts, no relationship between PE,
[E/yATP vs S phase fraction for human breast PC or PE plus PC with SPF was observed, possibly due to
29 cases. b, 18 aneuploid tumours; c, 11 diploid the smaller number of samples (aneuploid n= 11, total n=
18).
The in vitro values for the phospholipid metabolites are
2.21 ltmol g-' wet wt) between tumours. This not strictly comparable with the in vivo measurements but it
r the relative levels of PE (median: 24.6%, was not possible to calculate the level of PE or PC relative to
%) and PC (median: 9.05%, range: 2.5- yATP due to ATP hydrolysis to Pi during the inevitable delay
acid extractable phosphorus measured from between excision of tumour and storage in liquid nitrogen.
ctra in vitro. The concentration of PE in- Calculation of total phosphorus in vivo was not appropriate
(P = 0.0001) reflecting tumour cellularity. as the signal to noise often prevented detection of all the
om phosphorylated sugars, glycerol-3-phos- ATP peaks and also because the PDE peak contains reson-
rol-6-phosphate have been observed down- ances from membrane phospholipids.
) of PE in some 31P MR spectra in vitro. As cellular ATP is tightly regulated (Neeman & Degani,
ATP hydrolysis for all tumours during the 1989), PME relative to ATP may be indicative of intracel-
between surgical excision and freezing the lular levels, particularly as cellularity was highly variable as
nitrogen. PME and PDE are stable at room reflected by the wide range of concentrations for PE and PC.
up to 90 min (Smith et al., 1991). ATP production can be compromised by hypoxia and nutri-
ent deficiency (Freyer et al., 1990), but for human tumours
and tumourproliferation this represents a small proportion of the whole tumour
(Sutherland et al., 1988) and would not significantly affect
*elationship between DNA ploidy and the the tumour spectrum.
relative levels of PE, PC or PE plus PC. For The increase in PME/yATP for the tumour resistant to
icts no relationship was observed between tamoxifen is compatible with an association between PME/
icentration of PE (P = 0.62), PC (P = 0.45) yATP and proliferation. Tamoxifen was associated with
P = 0.45). Similarly there was no significant stable disease for the other two cases. The progressive reduc-
een SPF and the relative levels of PE (P= tion of PME/yATP for the second case is consistent with the
34) or PE plus PC (P = 0.34). This was also cytostatic action of tamoxifen. Replacement of viable cells by
Lalyses of aneuploid (n = 11) and diploid fibrosis could explain marked reduction of intensity of 31P
MR signal detected by 31pMRS for the third case. The initial
increase in PME/yATP may represent an initial tumour flare
due to the weak oestrogenic activity of tamoxifen.
The PME signal has contributions principally from PE and
PC with PE predominating. Other human tumours such as
depth resolved biochemical data by utilising meningioma (Kalra et al., 1991) and hepatic lymphoma
requency field produced by the transmitter (Dixon et al., 1991) are also rich in PE. For regenerating rat
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Figure 4 31P MR spectra from Case 1 studied a, before starting tamoxifen and b, 7 days later.
liver, the increase in the ratio of PE/PC from 12 h to 48 h
following partial hepatectomy appears to be mediated by
growth factor signalling as there was a parallel increase in the
second messenger, diacylglycerol (Murphy et al., 1992). Both
PE and PC can be produced by hydrolysis of the membrane
phospholipids, phosphatidylethanolamine (Kiss & Anderson,
1989) and phosphatidylcholine (Pelech & Vance, 1989)
respectively, by phospholipase C. Hydrolysis ofphosphatidyl-
choline by phospholipase D produces choline and phos-
phatidic acid which is then cleaved to diacylglycerol. It is not
clear if the phospholipase C and phospholipase D pathways
are activated together or preferentially (Price et al., 1989). In
human dermal fibroblasts the production ofdiacylglycerol by
EGF occurs primarily by phospholipase C (Fisher et al.,
1991). However, the source of PME in breast tumours is
unlikely to be due to cell signalling, as there was no relation-
ship between the pool of PME and EGFr level or status. The
role of phospholipid metabolites in cellular signalling is not
.'t31P MRS OF HUMAN BREAST CANCER AND PROLIFERATION 1151
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Figure 5 a, In vivo 31P MR spectra from a patient with breast cancer. b, High resolution 31P MR spectrum of a perchloric acid
extract of a sample of breast cancer from the same patient. PE = phosphoethanolamine, PC = phosphocholine, GPE = glycero-
phosphoethanolamine, GPC = glycerophosphocholine.
excluded as the change in pool size is likely to be small, or
absent as the fluxes of metabolites in and out of the pool
could be in balance.
The presence of high levels of PME in tumours may reflect
their role as membrane phospholipid precursors. It has been
suggested that the increased demand for membrane synthesis
in rapidly dividing cells leads to an increase in the synthetic
precursors (Radda et al., 1989). The CDP-choline pathway is
the predominant route for phosphatidylcholine synthesis in
eucaryotic cells (Figure 6). Upregulation of choline kinase
with increased production of PC (Warden & Friedken, 1985),
the precursor for the rate limiting step in this pathway may
account for increased PC in rapidly growing cells. In con-
trast, the contribution of the CDP-ethanolamine pathway to
phosphatidylethanolamine synthesis appears to depend upon
the supply of ethanolamine, at physiological levels this route
contributes about 30% of synthesis (Miller & Kent, 1986).
The CDP-choline and ethanolamine pathways have distinct1152 R. KALRA et al.
CDP CHOLINE PATHWAY CDP ETHANOLAMINE PATHWAY
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Figure 6 Pathways for biosynthesis of the major membrane phospholipids in mammalian cells.
enzymes (Pelech & Vance, 1984) and appear to be under
separate control as the incorporation of '4C-ethanolamine
into phospholipid is not directly related to the activity of the
enzymes involved (Groener et al., 1979). Decarboxylation of
phosphatidylserine with the production of ethanolamine is
known to be an important source of phosphatidylethanol-
amine (Bishop & Bell, 1988). Ethanolamine is also produced
by base exchange of free serine with the polar head group of
phosphatidylethanolamine, the major route for synthesis of
phosphatidylserine. High concentrations of ethanolamine are
toxic in cellular systems (Kaiho & Mizuno, 1985) and could
therefore be disposed of by conversion to PE in the CDP-
ethanolamine pathway.
In summary, this study demonstrates a significant associa-
tion between the relative level of PME to yATP and pro-
liferation for aneuploid tumours. The PME region contains
predominantly PE with a smaller contribution from PC. The
presence of these compounds may be a consequence of a shift
in the balance of phospholipid metabolism to synthesis with
more rapid synthesis in the faster growing tumours. Changes
in PME/'yATP observed following tamoxifen may be consis-
tent with the cytostatic effects of this drug. More cases need
to be studied but the low success rate here reflects the small
numbers of cases in published accounts. 31P MRS may only
be applicable for monitoring therapy in large tumours, asses-
sing novel agents and their metabolic effects.
Alteration in membrane composition can occur with malig-
nancy (Bergelson et al., 1970, 1974) and could influence the
levels of phospholipid precursors. We are therefore studying
the relationship between PME and membrane phospholipids.
This work was funded by the Medical Research Council, Imperial
Cancer Research Fund and by the John Radcliffe Hospital.
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